JP2005501857A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501857A5
JP2005501857A5 JP2003521237A JP2003521237A JP2005501857A5 JP 2005501857 A5 JP2005501857 A5 JP 2005501857A5 JP 2003521237 A JP2003521237 A JP 2003521237A JP 2003521237 A JP2003521237 A JP 2003521237A JP 2005501857 A5 JP2005501857 A5 JP 2005501857A5
Authority
JP
Japan
Prior art keywords
compound
sodium salt
temperature
fusion
crystalline sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003521237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501857A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/025675 external-priority patent/WO2003016315A1/en
Publication of JP2005501857A publication Critical patent/JP2005501857A/ja
Publication of JP2005501857A5 publication Critical patent/JP2005501857A5/ja
Withdrawn legal-status Critical Current

Links

JP2003521237A 2001-08-17 2002-08-13 Hivインテグラーゼ阻害剤のナトリウム塩 Withdrawn JP2005501857A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31337301P 2001-08-17 2001-08-17
PCT/US2002/025675 WO2003016315A1 (en) 2001-08-17 2002-08-13 Sodium salt of an hiv integrase inhibitor

Publications (2)

Publication Number Publication Date
JP2005501857A JP2005501857A (ja) 2005-01-20
JP2005501857A5 true JP2005501857A5 (enExample) 2006-01-05

Family

ID=23215462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521237A Withdrawn JP2005501857A (ja) 2001-08-17 2002-08-13 Hivインテグラーゼ阻害剤のナトリウム塩

Country Status (7)

Country Link
US (1) US6924282B2 (enExample)
EP (1) EP1430058A1 (enExample)
JP (1) JP2005501857A (enExample)
AR (1) AR036256A1 (enExample)
CA (1) CA2456206A1 (enExample)
DO (1) DOP2002000449A (enExample)
WO (1) WO2003016315A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326865B1 (en) * 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
WO2003077857A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
EP1646611A1 (en) * 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
SI1742642T1 (sl) * 2004-04-14 2009-04-30 Gilead Sciences Inc Fosfonatni analogi inhibitorskih spojin HIV integraze
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
US5681832A (en) 1995-02-17 1997-10-28 The United States Of America As Represented By The Department Of Health And Human Services Aroylaniline compounds, pharmaceutical compositions, and methods of using same to inhibit viral activity
US5945431A (en) 1996-03-15 1999-08-31 Biochem Therapeutics Incorporated Cytomegalovirus inhibiting compounds
AU4172197A (en) * 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
DE69828284T2 (de) 1997-06-30 2005-12-08 Nippon Kayaku K.K. Naphthyridinderivate oder salze davon
HUP0003258A3 (en) 1997-08-25 2001-05-28 Neurogen Corp Branford Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
EP1042295B1 (en) 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
US6380249B1 (en) 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
US6306891B1 (en) 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
WO2001000578A1 (en) 1999-06-25 2001-01-04 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
EP1326865B1 (en) * 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
DE122009000048I1 (de) 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase

Similar Documents

Publication Publication Date Title
JP2021530565A5 (enExample)
JP2023519891A5 (enExample)
JP2006519818A5 (enExample)
JP2020128376A5 (enExample)
JP2023534131A5 (enExample)
JP2009534468A5 (enExample)
JP2006526031A5 (enExample)
RU2013145518A (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
JP2011527333A5 (enExample)
JP2021501151A5 (enExample)
JP2009533410A5 (enExample)
JP2005503386A5 (enExample)
JP2007532560A5 (enExample)
JP2008525416A5 (enExample)
JP2010514806A5 (enExample)
JP2023036708A5 (enExample)
JP2010514807A5 (enExample)
JP2014503525A5 (enExample)
JP2012533550A5 (enExample)
JP2005520803A5 (enExample)
JP2013538849A5 (enExample)
CA2540768A1 (en) Pyrazolo and imidazo-pyrimidine derivatives
JP2013521301A5 (enExample)
JP2008507494A5 (enExample)
JP2005511697A5 (enExample)